Tenofovir and Hepatitis B Virus Transmission During Pregnancy
JAMA · 04.02.2025 · 333 (5) · 390
DOI: 10.1001/jama.2024.22952 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift JAMA, erschienen am 04.02.2025. Verfasst von Calvin Q Pan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Medical Research Institute of Infectious Diseases, Center for Liver Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical Univers…. Hauptthemen laut MEDLINE: Hepatitis B, Infectious Disease Transmission, Vertical, Pregnancy Complications, Infectious, Tenofovir. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Standard care for preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in highly viremic mothers consists of maternal antiviral prophylaxis beginning at gestational week 28 combined with an HBV vaccine series and HBV immune globulin (HBIG) at birth. However, HBIG is unavailable in some resource-limited areas.
Objective
To determine whether initiating tenofovir disoproxil fumarate (TDF) at gestational week 16 combined with HBV vaccinations for infants is noninferior to the standard care of TDF at gestational week 28 combined with HBV vaccinations and HBIG for infants in preventing MTCT in mothers with HBV and high levels of viremia. Design, Setting, and Participants An unblinded, 2-group, randomized, noninferiority clinical trial was conducted in 7 tertiary care hospitals in China. A total of 280 pregnant individuals (who all identified as women) with HBV DNA levels greater than 200 000 IU/mL were enrolled between June 4, 2018, and February 8, 2021. The final follow-up occurred on March 1, 2022.
Interventions
Pregnant individuals were randomly assigned to receive either TDF starting at gestational week 16 with HBV vaccinations for the infant or TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant. Main Outcomes and Measures The primary outcome was the MTCT rate, defined as detectable HBV DNA greater than 20 IU/mL or hepatitis B surface antigen positivity in infants at age 28 weeks. Noninferiority was established if the MTCT rate in the experimental group did not increase by more than an absolute difference of 3% compared with the standard care group, as measured by the upper limit of the 2-sided 90% CI.
Results
Among 280 pregnant individuals who enrolled in the trial (mean age, 28 years; mean gestational age at enrollment, 16 weeks), 265 (95%) completed the study. Among all live-born infants, using the last observation carried forward, the MTCT rate was 0.76% (1/131) in the experimental group and 0% (0/142) in the standard care group. In the per-protocol analysis, the MTCT rate was 0% (0/124) in the experimental group and 0% (0/141) in the standard care group. The between-group difference was 0.76% (upper limit of the 2-sided 90% CI, 1.74%) in all live-born infants and 0% (upper limit of the 2-sided 90% CI, 1.43%) in the per-protocol analysis. Both comparisons met the criterion for noninferiority. Rates of congenital defects and malformations were 2.3% (3/131) in the experimental group and 6.3% (9/142) in the standard care group (difference, 4% [2-sided 95% CI, −8.8% to 0.7%]). Conclusions and Relevance Among pregnant women with HBV and high levels of viremia, TDF beginning at gestational week 16 combined with HBV vaccination for infants was noninferior to the standard care of TDF beginning at gestational week 28 combined with HBIG and HBV vaccination for infants. These results support beginning TDF at gestational week 16 combined with infant HBV vaccine to prevent MTCT of HBV in geographic areas where HBIG is not available. Trial Registration ClinicalTrials.gov Identifier: NCT03476083
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangzhou Medical Research Institute of Infectious Diseases, Center for Liver Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
- Division of Gastroenterology, Department of Medicine, NYU Langone Medical Center, New York University Grossman School of Medicine, New York.
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.
- Department of Obstetrics and Gynecology, Shijiazhuang Maternity and Child Healthcare Hospital, Shijiazhuang, China.
- Department of Obstetrics and Gynecology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
- Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Pan, C. Q., Dai, E., Mo, Z., Zhang, H., Zheng, T. Q., Wang, Y., Liu, Y., Chen, T., Li, S., Yang, C., Wu, J., Chen, X., Zou, H., Mei, S., & Zhu, L. (2025). Tenofovir and Hepatitis B Virus Transmission During Pregnancy. JAMA, 333(5), 390. https://doi.org/10.1001/jama.2024.22952
Vancouver
Pan CQ, Dai E, Mo Z, Zhang H, Zheng TQ, Wang Y, et al. Tenofovir and Hepatitis B Virus Transmission During Pregnancy. JAMA. 2025;333(5):390. doi:10.1001/jama.2024.22952
BibTeX
@article{Pan2025,
author = {Pan, Calvin Q and Dai, Erhei and Mo, Zhongfu and Zhang, Hua and Zheng, Thomas Q and Wang, Yuming and Liu, Yingxia and Chen, Tianyan and Li, Suwen and Yang, Cuili and Wu, Jinjuan and Chen, Xiuli and Zou, Huaibin and Mei, Shanshan and Zhu, Lin},
title = {Tenofovir and Hepatitis B Virus Transmission During Pregnancy},
journal = {JAMA},
year = {2025},
volume = {333},
number = {5},
pages = {390},
doi = {10.1001/jama.2024.22952}
}
EUVIMED